Technology scale-up will unlock production of proteins that create sustainable stain-resistant paint, stronger Plexiglas, next-generation sweeteners, and purpose-built molecules that don’t yet exist
SEATTLE, (July 20, 2017) Arzeda, The Protein Design Company™, today announced that it had raised $12 million in a Series A round of funding led by OS Fund and including Bioeconomy Capital and Sustainable Conversion Ventures, as well as a follow-on investment from Arzeda’s seed investor, WRF Capital. Arzeda’s board will be expanded to include Jeff Klunzinger, Co-Founder at OS Fund.
SEATTLE (April 20, 2016) Gen9 and Arzeda today announced an agreement for the supply of megabase quantities of synthetic DNA that will enable Arzeda to accelerate development of novel molecules for its own products as well as those of its partners. The collaboration is part of Gen9’s MAP program, designed to provide industrial users of synthetic DNA with access to game-changing economics for synthetic DNA.
SEATTLE and EMERYVILLE, Calif. (March 21, 2016) Zymergen and Arzeda announced today a multi-year agreement to develop strains and processes to manufacture novel, high utility molecules and materials utilizing Arzeda’s pathway and enzyme design and Zymergen’s strain construction capabilities.
Arzeda will help further develop Stratos’ “Sequencing by Design” technology for rapid single molecule DNA sequencing
SEATTLE, November 11, 2015 – Biotechnology company Arzeda announced today an Agreement with Stratos Genomics to assist development of novel enzymes supporting Stratos’ DNA sequencing technology.